Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 631,600 shares, a growth of 140.0% from the April 30th total of 263,200 shares. Currently, 27.2% of the company’s stock are sold short. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 0.6 days.

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 25,000 shares of the stock in a transaction dated Tuesday, March 26th. The shares were acquired at an average price of $2.38 per share, for a total transaction of $59,500.00. Following the completion of the acquisition, the chief executive officer now owns 1,767 shares of the company’s stock, valued at approximately $4,205.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.07% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $34,000. CVI Holdings LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Bank of New York Mellon Corp acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $38,000. 3.55% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on TNXP shares. Roth Capital raised Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Thursday, April 18th. ValuEngine cut Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd.

TNXP traded up $0.02 during trading on Monday, reaching $1.61. 1,300 shares of the stock traded hands, compared to its average volume of 641,947. The stock has a market cap of $9.68 million, a PE ratio of -0.06 and a beta of 1.90. Tonix Pharmaceuticals has a fifty-two week low of $1.53 and a fifty-two week high of $48.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.54 and a current ratio of 9.54. The firm’s 50-day moving average price is $1.86.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, May 13th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.11). On average, equities research analysts expect that Tonix Pharmaceuticals will post -4.05 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Short Interest Update” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.

Read More: The components of the Stochastic Momentum Index

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.